ReviewPharmaceuticals (Basel, Switzerland)2020
The Rationale for Potential Pharmacotherapy of COVID-19.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis.Infection · 2022Pooled it
- Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis.Indian journal of medical microbiologyPooled it
- Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.Scientific reports · 2021Trial
- Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay.BMC infectious diseases · 2024Article
- Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.Journal of community hospital internal medicine perspectives · 2024Review
- Liver Injury Associated with COVID-19 Infection: Pathogenesis, Histopathology, Prognosis, and Treatment.Journal of clinical medicine · 2023Review
- Distinct Features of Vascular Diseases in COVID-19.Journal of inflammation research · 2023Review
- Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies.Hospital pharmacy · 2022Article
- Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19.International journal of molecular sciences · 2022Review
- Favipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial.EClinicalMedicine · 2022Article
- Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.Infection · 2022Review
- Clinical outcomes of immunomodulatory therapies in the management of COVID-19: A tertiary-care experience from Pakistan.PloS one · 2022Article
- Current Status of Baricitinib as a Repurposed Therapy for COVID-19.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Development and Validation of a Method for Quantification of Favipiravir as COVID-19 Management in Spiked Human Plasma.Molecules (Basel, Switzerland) · 2021Article
- Association of Early Favipiravir Use with Reduced COVID-19 Fatality among Hospitalized Patients.Infection & chemotherapy · 2021Article
- Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2021Review
- Role of favipiravir in the treatment of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Review
- COVID-19 in Solid Organ Transplant Recipients: a Review of the Current Literature.Current treatment options in infectious diseases · 2021Review
- COVID-19: The question of genetic diversity and therapeutic intervention approaches.Genetics and molecular biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On 11 March 2020, the coronavirus disease (COVID-19) was defined by the World Health Organization as a pandemic. Severe acute respiratory syndrome-2 (SARS-CoV-2) is the newly evolving human coronavirus infection that causes COVID-19, and it first appeared in Wuhan, China in December 2019 and spread rapidly all over the world. COVID-19 is being increasingly investigated through virology, epidemiology, and clinical management strategies. There is currently no established consensus on the standard of care in the pharmacological treatment of COVID-19 patients. However, certain medications suggested for other diseases have been shown to be potentially effective for treating this infection, though there has yet to be clear evidence. Therapies include new agents that are currently tested in several clinical trials, in addition to other medications that have been repurposed as antiviral and immune-modulating therapies. Previous high-morbidity human coronavirus epidemics such as the 2003 SARS-CoV and the 2012 Middle East respiratory syndrome coronavirus (MERS-CoV) prompted the identification of compounds that could theoretically be active against the emerging coronavirus SARS-CoV-2. Moreover, advances in molecular biology techniques and computational analysis have allowed for the better recognition of the virus structure and the quicker screening of chemical libraries to suggest potential therapies. This review aims to summarize rationalized pharmacotherapy considerations in COVID-19 patients in order to serve as a tool for health care professionals at the forefront of clinical care during this pandemic. All the reviewed therapies require either additional drug development or randomized large-scale clinical trials to be justified for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.